World On-Body Subcutaneous Injection Systems Market 2017: Therapeutic Drug Development / Drug Delivery Device Evolution / On-body SC System Enabling Technologies / Device-Drug Developer Collaborations

News provided by

Dec 21, 2017, 05:15 ET

DUBLIN, Dec. 21, 2017 /PRNewswire/ --

The "On-Body Subcutaneous Injection Systems" report has been added to Research and Markets' offering.

As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug marketers.

As the administration of injectables moves increasingly from practitioner offices and healthcare facilities to patient homes, decisions regarding as-supplied packaging that were once considered boilerplate have moved to the early stages of the development process. A wide spectrum of device attributes, including form factor, device-patient interaction, security and safety, dosing, activation, off-device communication, and drug formulation factors have been incorporated into drug injection devices. Over time, these initiatives will come to be expected by patients in injectable drugs.

What You Will Learn

What on-body subcutaneous systems are currently marketed or in development, who are the suppliers, and what are the device specifics?
What are the therapeutic markets being targeted by on-body subcutaneous injection systems?
What are the essential design factors, material selection issues, technologies and market development issues for on-body subcutaneous injection systems?
What are the major factors that will drive on-body subcutaneous injection systems demand?
How are on-body subcutaneous injection systems currently aligned with various drug classes and therapeutic markets?
What is the addressable market for on-body subcutaneous injection systems?
What is the expected impact of on-body subcutaneous injection systems on drug delivery markets?
Who are the significant players in this segment? What are their strategies? Who are their alliance partners?

Key Topics Covered:

1. Executive Summary

2. Subcutaneous Injectable Therapeutics Landscape

Therapeutic Drug Development
Drug Delivery Device Evolution
On-body SC System Enabling Technologies
Device-Drug Developer Collaborations

3. Device Design Factors

Primary Container
Injection Methodology
Electronics and System Features
Patient Interface

4. On-Body Subcutaneous Device Classes

Electronic Disposable
SmartDose
FlexTherapy
PrecisionTherapy
Electronic Semi-disposable
E3D Patch Pump
OmniPod (non-insulin version)
SensePatch SD
Unbranded (Medicom)
Mechanical Disposable
Enable Injector
Lapas AR
Libertas
Captive Devices
PatchPump
sc2Wear
Product Specific Devices
Neulasta On-body Injector

5. Near-term Product Analysis and Market Data

Blood Factors
Diuretics
Hematopoietics
Immunoglobulins
Monoclonal Antibodies
Prostacyclin
Gonadorelin

6. Market Factors

Regulatory Factors
Patient Training and Ease of Use
Adherence and Adverse Reactions

7. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/flj56w/world_onbody?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets